EURTAC

1. 01

   TKI-first treatment was favored despite the absence of an overall-survival difference at the time

2. 02

   Timely, interpretable genotyping was treated as a prerequisite for safe treatment selection

3. 03

   Modern intensification preferences were conditional, while predictive selection remained unresolved

4. 04

   Supportive care was integral to the amivantamab option, with anticoagulation duration still questioned

   Sample finding · free

   An audience participant in a YouTube panel asked when anticoagulation could end for patients taking amivantamab together with lazertinib. Another speaker asked whether anticoagulation should always accompany treatment that does not include amivantamab.

   Source: YouTube video, 2024-09-07 · paraphrased; the full report links the source

5. 05

   CNS control favored systemic treatment first, but selective local-treatment roles were retained

6. 06

   Historical-control questions exposed unresolved disagreement about mutation-associated prognosis

   Sample finding · free

   An audience participant in a YouTube discussion asked whether historical chemotherapy-only groups could establish a survival advantage for erlotinib without EURTAC’s direct comparison. A follow-up question requested numbers for the survival comparison.

   Source: YouTube video, 2012-10-12 · paraphrased; the full report links the source

7. 07

   The common-mutation treatment discussion did not translate into a single approach for uncommon sensitizing mutations

8. 08

   European confirmation was viewed as an access-enabling step, not merely replication of Asian findings

9. 09

   Retrospective commentary emphasized population selection and the provisional nature of clinical understanding

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2010-10-13 → 2026-01-15

Cited window

2010-10-13 → 2026-01-15

Retrieved

2026-10-08

Title

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Registry

NCT00446225

Study IDs

EURTAC-SLCG // GECP06/01 · 2006-003568-73

Sponsor

Spanish Lung Cancer Group

Design

Phase 3 · interventional, randomized, parallel, phase3

Status

Completed

Enrollment

174 actual

Start

2007-02-15 actual

Primary completion

2012-04-11 actual

Primary endpoint

Progression Free-survival

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
• –5 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –4 further source limits are recorded in the machine-readable scope of this record.
• –The reviewed public material is not representative of all HCPs. Some recordings were unavailable, and discussions using unnamed or variant references to the trial may be missing.
• –Publication and upload dates do not establish the exact session or readout date. They also do not demonstrate a change of mind across settings.
• –Similar content in separate recordings is not counted as independent HCP agreement. Source-native names are retained, and unnamed passages are not assigned to roster participants.
• –Several survival statements concern the reporting time and crossover interpretation rather than the final status of all later EURTAC analyses.
• –Approximate or inconsistent numbers remain what speakers said. Bossaer's 0.037 European-study hazard ratio lacks an endpoint in the passage, and his iPASS account explicitly says the 0.48 estimate followed exclusion of EGFR-mutated patients.
• –Historical approval, access and dosing statements are not current guidance, and individual prophylaxis or toxicity-management practices are not universal protocols.
• –The original protocol and some linked full-text or regulatory material were unavailable, limiting how completely the underlying evidence can resolve questions raised in the commentary.
• –The report retains the separate Chinese-study early-use interpretation but does not label that study's estimates as EURTAC results.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch. No corrections.

release b75a07513c2f776240bd399fa7584154ee130c4a28e893ad5b81df97f9204552

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/eurtac-nct00446225.json
curl https://www.erudio.com/reports/eurtac-nct00446225.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "eurtac-00446225" })